Recombinant anti-Human CD28 mAb

CD28 molecule is present on the surface of most T cells and is considered a surface molecule unique to T cells. However, not only the first signal of the T lymphocyte receptor (TCR)/CD3 complex is required during the full activation of T lymphocytes, but also the second signal, to enhance the activation and proliferation of T lymphocytes. The synergistic stimulation molecule CD28 is present on the surface of T lymphocytes, and its interaction with its ligand B7 is one of the major pathways to provide the second signal for T lymphocyte activation. T lymphocytes will be fully activated if the second signal is provided through the synergistic stimulation of the CD28 antibody while providing the first signal using the simulation of the CD3 antibody in vitro. Recombinant Anti-Human CD28 mAb is expressed by mammalian cells, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.